Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
Recruiting · NCT07146100 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ausper Biopharma Co., Ltd.
View the official record on ClinicalTrials.gov →What this trial is about
This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Capable of giving informed consent.
- Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.
Exclusion criteria
- Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137.
- Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.
Where it is running
37 locations listed.
- AusperBio Investigational Site - Hefei, Anhui, China
- AusperBio Investigational Site - Beijing, Beijing Municipality, China
- AusperBio Investigational Site - Chongqing, Chongqing Municipality, China
- AusperBio Investigational Site - Chongqing, Chongqing Municipality, China
- AusperBio Investigational Site - Fuzhou, Fujian, China
- AusperBio Investigational Site - Xiamen, Fujian, China
- AusperBio Investigational Site - Lanzhou, Gansu, China
- AusperBio Investigational Site - Foshan, Guangdong, China
- AusperBio Investigational Site - Guangzhou, Guangdong, China
- AusperBio Investigational Site - Guangzhou, Guangdong, China
- AusperBio Investigational Site - Guangzhou, Guangdong, China
- AusperBio Investigational Site - Guangzhou, Guangdong, China
- AusperBio Investigational Site - Shenzhen, Guangdong, China
- AusperBio Investigational Site - Shenzhen, Guangdong, China
- AusperBio Investigational Site - Liuzhou, Guangxi, China
- AusperBio Investigational Site - Nanning, Guangxi, China
- AusperBio Investigational Site - Zunyi, Guizhou, China
- AusperBio Investigational Site - Haikou, Hainan, China
- AusperBio Investigational Site - Zhengzhou, Henan, China
- AusperBio Investigational Site - Wuhan, Hubei, China
- AusperBio Investigational Site - Changsha, Hunan, China
- AusperBio Investigational Site - Changsha, Hunan, China
- AusperBio Investigational Site - Changhou, Jiangsu, China
- AusperBio Investigational Site - Nanjing, Jiangsu, China
- AusperBio Investigational Site - Zhenjiang, Jiangsu, China
- AusperBio Investigational Site - Nanchang, Jiangxi, China
- AusperBio Investigational Site - Changchun, Jilin, China
- AusperBio Investigational Site - Shenyang, Liaoning, China
- AusperBio Investigational Site - Shanghai, Shanghai Municipality, China
- AusperBio Investigational Site - Taiyuan, Shanxi, China
- AusperBio Investigational Site - Xi’an, Shanxi, China
- AusperBio Investigational Site - Chengdu, Sichuan, China
- AusperBio Investigational Site - Chengdu, Sichuan, China
- AusperBio Investigational Site - Kunming, Yunnan, China
- AusperBio Investigational Site - Hangzhou, Zhejiang, China
- AusperBio Investigational Site - Hangzhou, Zhejiang, China
- AusperBio Investigational Site - Hangzhou, Zhejiang, China